BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang G, Zhao K, Reynaud-Mougin C, Loft H, Ren H, Eriksen HF, Ettrup A. Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder. Curr Med Res Opin 2020;36:875-82. [PMID: 31990207 DOI: 10.1080/03007995.2020.1723072] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Danielak D. Vortioxetine in management of major depressive disorder - a favorable alternative for elderly patients? Expert Opin Pharmacother 2021;22:1167-77. [PMID: 33650935 DOI: 10.1080/14656566.2021.1880567] [Reference Citation Analysis]
2 Yang YK, Chen CS, Tsai CF, Chang CM, Lai TJ, Lee CT, Lin CC, Lan TH, Herr KJ. A Taiwanese study on real-world evidence with vortioxetine in patients with major depression in Asia (TREVIDA). Curr Med Res Opin 2021;:1-11. [PMID: 34515596 DOI: 10.1080/03007995.2021.1980869] [Reference Citation Analysis]
3 Ye X, Wang D, Zhu H, Wang D, Li J, Tang Y, Wu J. Gut Microbiota Changes in Patients With Major Depressive Disorder Treated With Vortioxetine. Front Psychiatry 2021;12:641491. [PMID: 34025474 DOI: 10.3389/fpsyt.2021.641491] [Cited by in F6Publishing: 1] [Reference Citation Analysis]